Trial Profile
A Study to Evaluate the Risk for Gastrointestinal Perforation among Rheumatoid Arthritis Patients who Received Tofacitinib, Tocilizumab, or other Biologics
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jun 2016
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 24 Jun 2016 New trial record
- 23 May 2016 Results published in the Arthritis and Rheumatology